After more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del…
en_news
The sports association “Els Veterans de Vilablareix” is a non-profit organisation that organises a wide range of sporting and leisure…
On April 9, the CRIS Cancer Foundation held the 2026 “CRIS Science Day” featuring the III CRIS International Symposium, focused…
Sponsored by F. Hoffmann-La Roche Ltd, in collaboration with Vall d’Hebron Institute of Oncology (VHIO), a first-in-human clinical trial was…
The Vall d’Hebron Institute of Oncology (VHIO) hosted the 3rd PragmaTIL Annual Meeting on March 26–27 in Barcelona, bringing together consortium partners to review the project’s…
The single arm phase II CALYPSO study evaluated the efficacy of MET inhibitor savolitinib combined with PD-L1 inhibitor durvalumab in…
Today, March 31, marks World Colorectal Cancer Day, an occasion to raise awareness about one of the most common cancers…
Last Wednesday, March 25, marked the end of the third edition of VHIO4STEM, VHIO’s mentorship programme that connects 4th ESO…
Under the agreement, IQVIA will preferentially offer Vall d’Hebron clinical studies managed by the company. Vall d’Hebron Barcelona Hospital Campus…
The Vall d’Hebron Barcelona Hospital Campus and Biocat held a new session of the ATMP Catalonia Series, titled ‘ATMPs: From…
